drugset
drugset / Trial / NCT03381404

Mass Balance Study With MT-8554

NCT03381404 ↗

Phase 1 Completed 6 enrolled Tanabe Pharma America, Inc.
NaSingle-groupOpen-labelOther

Summary

This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of \[14C\] MT 8554.

Timeline

Start
2017-12-19
Primary completion
2018-01-29
Completion
2018-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule — Oral

Indications

No indication recorded.